Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

170.92USD
3:13pm EDT
Change (% chg)

$-2.01 (-1.16%)
Prev Close
$172.93
Open
$173.10
Day's High
$173.42
Day's Low
$170.58
Volume
982,109
Avg. Vol
1,618,771
52-wk High
$201.23
52-wk Low
$152.16

Latest Key Developments (Source: Significant Developments)

Amgen Plans To Build A New Biomanufacturing Plant in Rhode Island
Tuesday, 10 Apr 2018 12:07pm EDT 

April 10 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES RHODE ISLAND WILL BE LOCATION OF FIRST US NEXT-GENERATION BIOMANUFACTURING PLANT.FOLLOWING RECENT U.S. FEDERAL TAX REFORM, CO MADE DECISION TO LOCATE NEW PLANT IN U.S. RHODE ISLAND.  Full Article

EU Medicines Agency Recommends Approval Of Amgen Europe, Sandoz Biosimilar Drugs
Friday, 23 Mar 2018 08:57am EDT 

March 23 (Reuters) - EU Medicines Agency: :EU MEDICINES AGENCY RECOMMENDS APPROVAL OF AMGEN EUROPE'S BIOSIMILAR DRUG FOR TREATMENT OF BREAST AND GASTRIC CANCER.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF SANDOZ'S BIOSIMILAR DRUG FOR TREATMENT OF RHEUMATOID ARTHRITIS, CROHN'S DISEASE, ULCERATIVE COLITIS, ETC. .  Full Article

CHMP Recognizes That Amgen's Repatha Prevents Heart Attacks And Strokes
Friday, 23 Mar 2018 08:44am EDT 

March 23 (Reuters) - Amgen Inc ::AMGEN RECEIVES POSITIVE CHMP OPINION RECOGNIZING THAT REPATHA (EVOLOCUMAB) PREVENTS HEART ATTACKS AND STROKES.AMGEN INC - RECOMMENDED LABEL INCLUDES NEW INDICATION BASED ON REPATHA CARDIOVASCULAR OUTCOMES STUDY.  Full Article

Amgen And Allergan Receive Positive CHMP Opinion For Abp 980
Friday, 23 Mar 2018 08:41am EDT 

March 23 (Reuters) - Allergan Plc ::AMGEN AND ALLERGAN RECEIVE POSITIVE CHMP OPINION FOR ABP 980 (BIOSIMILAR HERCEPTIN®) FOR THE TREATMENT OF THREE TYPES OF CANCER.AMGEN ‍RECOMMENDED FOR APPROVAL FOR SAME INDICATIONS AS HERCEPTIN​.AMGEN CHMP POSITIVE OPINION FOR ABP 980 WILL NOW BE REVIEWED BY EUROPEAN COMMISSION.  Full Article

Amgen Inc Sets Quarterly Dividend Of $1.32 Per Share
Wednesday, 7 Mar 2018 04:15pm EST 

March 7 (Reuters) - Amgen Inc ::SETS QUARTERLY DIVIDEND OF $1.32 PER SHARE.  Full Article

Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta
Tuesday, 27 Feb 2018 09:00am EST 

Feb 27 (Reuters) - Amgen Inc ::AMGEN RECEIVES POSITIVE CHMP OPINION FOR DELIVERY SYSTEM OF NEULASTA® (PEGFILGRASTIM).AMGEN INC - CHMP OF EMA ISSUED A POSITIVE OPINION RECOMMENDING A LABEL VARIATION FOR NEULASTA TO INCLUDE NEULASTA ONPRO KIT.  Full Article

Abarca, Amgen Enter Outcomes-Based Agreement For Repatha
Thursday, 22 Feb 2018 11:59am EST 

Feb 22 (Reuters) - Amgen Inc ::‍ABARCA SAYS SIGNED OUTCOMES-BASED CONTRACT WITH AMGEN FOR CHOLESTEROL-LOWERING DRUG, REPATHA​.  Full Article

Amgen Inc Q4 Loss Per Share $5.89
Thursday, 1 Feb 2018 04:01pm EST 

Feb 1 (Reuters) - Amgen Inc ::AMGEN QTRLY LOSS PER SHARE $5.89; QTRLY ADJUSTED EARNINGS PER SHARE $2.89; QTRLY REVENUE $5.80 BILLION, DOWN 3 PERCENT.AMGEN - QTRLY LOSS PER SHARE INCLUDES $6.1 BILLION CHARGE RELATED TO IMPACT OF U.S. TAX REFORM.AMGEN SEES 2018 TOTAL REVENUE $21.8 BILLION - $22.8 BILLION; SEES 2018 EARNINGS PER SHARE $11.18 - $12.36; SEES 2018 ADJUSTED EARNINGS PER SHARE $12.60 - $13.70.AMGEN SEES 2018 CAPITAL EXPENDITURES TO BE ABOUT $750 MILLION.AMGEN - ADDITIONAL $10 BILLION OF SHARE REPURCHASES AUTHORIZED.AMGEN - NEW INVESTMENT PLAN INCLUDES COMMITTING UP TO $300 MILLION TO BUILD NEW MANUFACTURING PLANT IN THE U.S..AMGEN - EXPECTS TO INVEST ABOUT $3.5 BILLION IN CAPITAL EXPENDITURES OVER NEXT 5 YRS, WITH ABOUT 75 PERCENT OF INVESTMENT IN THE U.S..AMGEN - EXPECTS TO FINALIZE EXACT LOCATION OF NEW MANUFACTURING PLANT IN Q2.AMGEN - INCREASING SIZE OF AMGEN VENTURES FUND, PROVIDING UP TO $300 MILLION GROWTH CAPITAL FOR EARLY STAGE, BIOTECH COS IN THE U.S..  Full Article

FDA Approves Addition Of Overall Survival Data To Kyprolis Label
Wednesday, 17 Jan 2018 04:15pm EST 

Jan 17 (Reuters) - Amgen Inc ::FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLIS® (CARFILZOMIB) LABEL.AMGEN INC - U.S. FDA APPROVED SUPPLEMENTAL NEW DRUG APPLICATION TO ADD OVERALL SURVIVAL DATA FROM PHASE 3 TRIAL TO PRESCRIBING INFORMATION FOR KYPROLIS.  Full Article

Amgen Expects To Launch Migraine Drug This Year
Tuesday, 9 Jan 2018 11:55am EST 

Jan 9 (Reuters) - Amgen Inc ::AMGEN CEO SAYS EXPECTS TO BE ABLE TO LAUNCH AIMOVIG FOR MIGRAINE THIS YEAR.AMGEN SAYS EXPECTS TO LAUNCH HUMIRA BIOSIMILAR OUTSIDE U.S. THIS YEAR.AMGEN CEO SAYS BUSINESS DEVELOPMENT DEALS TO REMAIN PRIORITY IN 2018.AMGEN CEO SAYS COMPANY IN STRONGER STRATEGIC POSITION AFTER TAX REFORM.  Full Article

Photo

Amgen's Aimovig halved migraine days in 30 percent of trial patients

LOS ANGELES A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.